Compare Stocks: KOD, UTHR, GMAB, and BNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$90.20 +1.7%	$99.12	$79.52 ▼ $124.00	$22.42B	1.25	1.01 million shs	1.08 million shs
GMAB Genmab A/S	$37.82 +2.5%	$34.25	$23.62 ▼ $40.17	$23.02B	0.81	4.05 million shs	4.08 million shs
KOD Kodiak Sciences	$88.12 +8.7%	$51.74	$13.95 ▼ $104.00	$5.10B	2.03	3.97 million shs	1.39 million shs
UTHR United Therapeutics	$541.51 +0.3%	$513.58	$409.07 ▼ $609.35	$23.16B	0.49	1.04 million shs	532,388 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-0.39%	-6.92%	-10.32%	-3.17%	-13.60%
GMAB Genmab A/S	+0.88%	+0.65%	+12.99%	+27.29%	+12.64%
KOD Kodiak Sciences	-11.50%	-10.97%	+144.69%	+96.58%	+549.76%
UTHR United Therapeutics	-0.62%	-0.91%	+7.43%	+2.08%	+24.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$90.20 +1.7%	$99.12	$79.52 ▼ $124.00	$22.42B	1.25	1.01 million shs	1.08 million shs
GMAB Genmab A/S	$37.82 +2.5%	$34.25	$23.62 ▼ $40.17	$23.02B	0.81	4.05 million shs	4.08 million shs
KOD Kodiak Sciences	$88.12 +8.7%	$51.74	$13.95 ▼ $104.00	$5.10B	2.03	3.97 million shs	1.39 million shs
UTHR United Therapeutics	$541.51 +0.3%	$513.58	$409.07 ▼ $609.35	$23.16B	0.49	1.04 million shs	532,388 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-0.39%	-6.92%	-10.32%	-3.17%	-13.60%
GMAB Genmab A/S	+0.88%	+0.65%	+12.99%	+27.29%	+12.64%
KOD Kodiak Sciences	-11.50%	-10.97%	+144.69%	+96.58%	+549.76%
UTHR United Therapeutics	-0.62%	-0.91%	+7.43%	+2.08%	+24.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.65	Moderate Buy	$125.44	38.89% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$42.50	11.56% Upside
KOD Kodiak Sciences	2.63	Moderate Buy	$104.71	18.54% Upside
UTHR United Therapeutics	2.71	Moderate Buy	$642.69	17.42% Upside

Current Analyst Ratings Breakdown

Latest KOD, UTHR, GMAB, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	UTHR United Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell	$368.00
10/14/2026	UTHR United Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$728.00
10/14/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$136.00 ➝ $132.00
10/12/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$96.00 ➝ $126.00
10/8/2026	UTHR United Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$677.00 ➝ $708.00
10/8/2026	BNTX BioNTech	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Hold
10/7/2026	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$115.00 ➝ $114.00
10/7/2026	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$40.00 ➝ $45.00
10/7/2026	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$40.00 ➝ $50.00
10/7/2026	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$515.00 ➝ $566.00
10/6/2026	KOD Kodiak Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.65B	8.62	$1.35 per share	66.67	$96.59 per share	0.94
GMAB Genmab A/S	$4.13B	5.75	$1.68 per share	22.72	$9.10 per share	4.19
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A
UTHR United Therapeutics	$3.18B	7.38	$33.23 per share	16.47	$164.81 per share	3.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	29.99	23.66	1.69	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	19.60	18.05	3.89	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest KOD, UTHR, GMAB, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	KOD Kodiak Sciences	-$1.06	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	GMAB Genmab A/S	$0.37	N/A	N/A	N/A	$1.20 billion	N/A
11/4/2026	Q3 2026	UTHR United Therapeutics	$6.21	N/A	N/A	N/A	$784.57 million	N/A
11/3/2026	Q3 2026	BNTX BioNTech	$0.8940	N/A	N/A	N/A	$1.20 billion	N/A
8/13/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	$1.53	1.72%	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	7.80
GMAB Genmab A/S	0.81	2.46	2.44
KOD Kodiak Sciences	N/A	2.49	2.49
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
GMAB Genmab A/S	7.07%
KOD Kodiak Sciences	89.06%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
GMAB Genmab A/S	1.54%
KOD Kodiak Sciences	44.40%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
GMAB Genmab A/S	3,029	624.06 million	614.45 million	Optionable
KOD Kodiak Sciences	124	62.85 million	34.94 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

KOD, UTHR, GMAB, and BNTX Headlines

Recent News About These Companies

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

3 hours ago | marketbeat.com

United Therapeutics (UTHR) Settles Litigation And Resets Pulmonary Hypertension Competition

October 15 at 11:51 AM | finance.yahoo.com

Is United Therapeutics (UTHR) Undervalued After Its Legal Settlement?

October 15 at 6:51 AM | uk.finance.yahoo.com

United Therapeutics (UTHR) Stock May Be Undervalued Following The Litigation Settlement

October 15 at 6:51 AM | finance.yahoo.com

What to Know as Liquidia, United Therapeutics Settlement Sends LQDA Stock Soaring

October 14 at 4:51 PM | barchart.com

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

October 14 at 2:41 PM | zacks.com

Liquidia shares surge 25% as settlement ends United Therapeutics litigation

October 14 at 1:16 PM | proactiveinvestors.com

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

October 14 at 12:40 PM | zacks.com

United Therapeutics Corp. (UTHR) PT Raised to $728 at Jefferies

October 14 at 12:40 PM | streetinsider.com

LQDA stock rockets 40% today – BTIG calls United Therapeutics settlement better than best-case scenario

October 14 at 12:40 PM | msn.com

Liquidia adds over 30% on United Thera. settlement; BTIG upgrades

October 14 at 12:40 PM | seekingalpha.com

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

October 14 at 12:40 PM | finance.yahoo.com

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

October 14 at 11:30 AM | 247wallst.com

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

October 14 at 11:05 AM | 247wallst.com

Liquidia shares jump as United Therapeutics settlement clears major YUTREPIA overhang

October 14 at 10:51 AM | quiverquant.comQ

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

October 14 at 9:56 AM | zacks.com

This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.

October 14 at 8:57 AM | barrons.com

Liquidia Settles Bitter Fight With United Therapeutics

October 14 at 8:30 AM | benzinga.com

United Therapeutics Reaches Major Pulmonary Hypertension Settlement

October 14 at 7:51 AM | tipranks.com

Liquidia Reaches Global Patent Settlement, Refines Financing

October 14 at 6:30 AM | tipranks.com

Liquidia Stock (LQDA) Pops as $380.7M Deal Ends Legal Battle with United Therapeutics

October 14 at 5:11 AM | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, UTHR, GMAB, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

$90.20 +1.54 (+1.74%)

Closing price 04:00 PM Eastern

Extended Trading

$90.50 +0.30 (+0.33%)

As of 07:39 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Genmab A/S NASDAQ:GMAB

$37.82 +0.93 (+2.52%)

Closing price 04:00 PM Eastern

Extended Trading

$37.82 0.00 (0.00%)

As of 07:30 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Kodiak Sciences NASDAQ:KOD

$88.12 +7.03 (+8.67%)

Closing price 04:00 PM Eastern

Extended Trading

$88.25 +0.13 (+0.15%)

As of 07:56 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

United Therapeutics NASDAQ:UTHR

$541.51 +1.48 (+0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$541.55 +0.04 (+0.01%)

As of 07:30 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, UTHR, GMAB, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, UTHR, GMAB, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, UTHR, GMAB, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, UTHR, GMAB, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

Genmab A/S NASDAQ:GMAB

Kodiak Sciences NASDAQ:KOD

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, UTHR, GMAB, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, UTHR, GMAB, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, UTHR, GMAB, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, UTHR, GMAB, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

Genmab A/S NASDAQ:GMAB

Kodiak Sciences NASDAQ:KOD

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools